Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 August 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Direct acting antivirals for the treatment of mixed cryoglobulinemia

The latest issue of the American Journal of Gastroenterology examines the efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia.

News image

Mixed cryoglobulinemia is strongly associated with hepatitis C virus (HCV) infection and ranges from being asymptomatic to causing life-threatening vasculitis.

In those with symptoms, treatment with pegylated interferon (pegIFN) and ribavirin (RBV) reduces mortality.

However, few data are available on the safety and efficacy of antiviral therapy with direct acting antivirals in the treatment of HCV-related cryoglobulinemia.

Dr Jordan Feld and colleagues from Canada retrospectively evaluated at a tertiary care center of patients treated for HCV-related cryoglobulinemia with DAA±pegIFN.

The researchers primary outcomes were virological, immunological, and clinical response.

Cryoglobulins disappeared in 29% symptomatic patients
American Journal Gastroenterology

Complete, partial, or non-response were used to describe change in cryocrit or vasculitic manifestations at week 12 post treatment.

Side effects, hospitalizations, and decompensating events were recorded.

The research team examined 18 symptomatic and 65 asymptomatic patients were reviewed including 10 with severe/life-threatening vasculitis.

The team found that 80% of patients received pegIFN-free therapy.

Sustained virological response was attained in 89% symptomatic, and 91% were asymptomatic patients.

The research team observed that cryoglobulins disappeared in 29% symptomatic, and 53% asymptomatic patients.

Of symptomatic patients with sustained virological response, clinical response was complete in 39%, and partial response in 22%.

Of the 5 viral relapsers, the research team found that 1 had a complete response during therapy with no symptomatic recurrence, while the other patients had no clinical response.

Among 7 with severe vasculitis, 6 achieved sustained virological response but only 1 had a complete clinical response, with 3 showing a partial response and 2 showing no improvement.

All 4 with life-threatening vasculitis required plasmapheresis, and 3 received rituximab.

All achieved sustained virological response leading to partial clinical response in two, but no response in 2.

Skin manifestations were most likely to completely resolve with lower responses seen in renal, and neurological symptoms.

The researchers noted that 99% of patients completed therapy, with 23% reporting adverse events.

Hospitalization for decompensation or worsening vasculitis occurred in 6%, and 22% patients, respectively.

Dr Feld's team concludes, "Direct acting antivirals resulted in high rates of sustained virological response in patients with cryoglobulinemia."

"Safety and tolerability were excellent."

"However, most patients did not have a complete clinical or immunological response, suggesting a delay to clinical response particularly in those with severe/life-threatening vasculitis."

"Further follow-up will be required to determine if clinical improvement continues after viral clearance."

Am J Gastroenterol 2017; 112: 1298–1308
11 August 2017

Go to top of page Email this page Email this page to a colleague

 22 August 2017 
Survival in patients with Lynch syndrome
 22 August 2017 
Improving the diagnostic accuracy of severe liver fibrosis in NAFLD
 22 August 2017 
New therapies to manage Hep B
 21 August 2017 
Treatments for chronic idiopathic constipation
 21 August 2017 
Improving medication adherence in IBD
 21 August 2017 
Ethnic disparities for chronic Hep C survival
 18 August 2017 
Proteomic analysis of IBD
 18 August 2017 
Pediatric intestinal failure
 18 August 2017 
Anti-TNF treatment and bowel resection in Crohn's
 17 August 2017 
Outcomes of ulcerative colitis patients undergoing pouch surgery
 17 August 2017 
Mortality in patients with asymptomatic pancreatic cystic neoplasms
 17 August 2017 
Survival after primary tumor resection in advanced colorectal cancer
 16 August 2017 
Assessment of seronegative villous atrophy
 16 August 2017 
Appendectomy and colectomy risk in ulcerative colitis
 16 August 2017 
Gluten sensitivity and celiac disease
 15 August 2017 
Infliximab and treatment failure during maintenance
 15 August 2017 
Genetic in idiopathic pancreatitis
 15 August 2017 
Genetic factors and tobacco in IBD
 14 August 2017 
Per oral endoscopic myotomy
 14 August 2017 
Early colonoscopy and symptomatic colorectal cancer
 14 August 2017 
Ethnic disparities and Hep C survival
 11 August 2017 
Ledipasvir and sofosbuvir in treatment-naïve Hep C
 11 August 2017 
EBV DNA to screen for nasopharyngeal cancer
 11 August 2017 
Direct acting antivirals and mixed cryoglobulinemia
 10 August 2017 
Routine preoperative laboratory tests for elective surgery
 10 August 2017 

Whole-genome sequencing in primary care

 10 August 2017 
Mortality in cirrhosis
 09 August 2017 
Anticoagulants in cirrhosis
 09 August 2017 
Low birthweight and pediatric NAFLD
 09 August 2017 
IBS with extraintestinal somatic and psychological symptoms
 08 August 2017 
Prior Barrett’s diagnosis and esophageal cancer survival
 08 August 2017 
Imaging index for fistulizing Crohn's
 08 August 2017 
Statin use after colon cancer
 07 August 2017 
Contraindications of biologic therapies in IBD
 07 August 2017 
Predicting clinical outcome in colorectal cancer
 07 August 2017 
Future burden of esophageal cancer
 04 August 2017 
Internet decision-making resources for ulcerative colitis surgery
 04 August 2017 
Distal findings and proximal colorectal neoplasia
 04 August 2017 
CT colonography vs flexible sigmoidoscopy
 03 August 2017 
Bloating and abdominal distension
 03 August 2017 
Predictors of colectomy in ulcerative colitis
 03 August 2017 
Treatment for sensitized transplant patients
 02 August 2017 
Preventing reactivation of Hep B
 02 August 2017 
Improving medication adherence in IBD
 02 August 2017 
Multiply recurrent C. difficile in the USA
 01 August 2017 
Coping with IBD
 01 August 2017 
Hepatocellular carcinoma in autoimmune hepatitis
 01 August 2017 
Anti-TNF treatment in Crohn's disease
 31 July 2017 
Global HCV incidence and mortality elimination targets
 31 July 2017 
Diagnosing GERD
 31 July 2017 
Diagnostic accuracy of severe liver fibrosis in patients with NAFLD
 28 July 2017 
Low FODMAP diet in IBS
 28 July 2017 
IBD patient–centered medical home
 28 July 2017 
Excluding NAFLD in the general population
 27 July 2017 
H. pylori infection and preeclampsia
 27 July 2017 
Colorectal cancer increases in developed and developing regions
 27 July 2017 
Anger in HIV-HCV co-infected patients
 26 July 2017 
Treating chronic pancreatitis
 26 July 2017 
Colorectal cancer screening
 26 July 2017 
Factors that influence H. pylori gastritis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us